Dr He on the Evaluation of Camrelizumab Plus Rivoceranib in Unresectable HCC
Aiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
Medstar Georgetown University Hospital Biliary Cancers Aiwu Ruth He Unresectable Hcc Cares 310 Hepatocellular Carcinoma
Source: onclive.com